Ameritas Investment Partners’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-4,834
| Closed | -$11K | – | 3146 |
|
|
2024
Q2 | $11K | Buy |
+4,834
| New | +$18.5K | ﹤0.01% | 2888 |
|
|
2022
Q2 | – | Sell |
-2,920
| Closed | -$22K | – | 3281 |
|
|
2022
Q1 | $22K | Hold |
2,920
| – | – | ﹤0.01% | 2529 |
|
|
2021
Q4 | $30K | Hold |
2,920
| – | – | ﹤0.01% | 2447 |
|
|
2021
Q3 | $39K | Hold |
2,920
| – | – | ﹤0.01% | 2329 |
|
|
2021
Q2 | $64K | Hold |
2,920
| – | – | ﹤0.01% | 2025 |
|
|
2021
Q1 | $70K | Hold |
2,920
| – | – | ﹤0.01% | 1881 |
|
|
2020
Q4 | $53K | Hold |
2,920
| – | – | ﹤0.01% | 1964 |
|
|
2020
Q3 | $34K | Hold |
2,920
| – | – | ﹤0.01% | 2082 |
|
|
2020
Q2 | $71K | Hold |
2,920
| – | – | ﹤0.01% | 1619 |
|
|
2020
Q1 | $32K | Hold |
2,920
| – | – | ﹤0.01% | 1916 |
|
|
2019
Q4 | $77K | Hold |
2,920
| – | – | ﹤0.01% | 1658 |
|
|
2019
Q3 | $67K | Hold |
2,920
| – | – | ﹤0.01% | 1708 |
|
|
2019
Q2 | $90K | Buy |
2,920
+1,302
| +80% | +$27.4K | ﹤0.01% | 1572 |
|
|
2019
Q1 | $27K | Hold |
1,618
| – | – | ﹤0.01% | 2229 |
|
|
2018
Q4 | $31K | Hold |
1,618
| – | – | ﹤0.01% | 2076 |
|
|
2018
Q3 | $85K | Hold |
1,618
| – | – | ﹤0.01% | 1676 |
|
|
2018
Q2 | $70K | Buy |
1,618
+478
| +42% | +$20.5K | ﹤0.01% | 1784 |
|
|
2018
Q1 | $42K | Buy |
1,140
+470
| +70% | +$12.5K | ﹤0.01% | 2013 |
|
|
2017
Q4 | $13K | Buy |
+670
| New | +$14.4K | ﹤0.01% | 2668 |
|
Ameritas Investment Partners's GTHX Position: Q3 2024 in Review
Ameritas Investment Partners sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 4,834 shares — an estimated $11K sold.
Ameritas Investment Partners first reported a position in GTHX in Q4 2017 and held it in 19 quarters. The position peaked at $90K in Q2 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Ameritas Investment Partners reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Ameritas Investment Partners sold 4,834 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $11K.
- Ameritas Investment Partners first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 19 quarters.
- Ameritas Investment Partners's G1 Therapeutics, Inc. Common Stock position peaked at $90K in Q2 2019.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Ameritas Investment Partners's 13F filing for Q3 2024, filed 13 Nov 2024.